Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Fineline Cube May 18, 2026
Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Fineline Cube May 18, 2026
Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Fineline Cube May 18, 2026
Company Deals

Boehringer Ingelheim and Tempus Forge Multi-Year AI-Driven Oncology Drug Development Partnership

Fineline Cube May 16, 2025

Germany-based pharmaceutical major Boehringer Ingelheim has entered into a multi-year strategic collaboration with Tempus (NASDAQ:...

Company Deals

Hainan Haiyao and Elken Global Form Five-Year Strategic Partnership in Wellness Products

Fineline Cube May 16, 2025

China-based Hainan Haiyao Co., Ltd. (SHE: 000566) has entered into a five-year strategic collaboration agreement...

Company Medical Device

Beijing Balance Medical’s Renato System Gets NMPA Approval for Valve-in-Valve Therapy

Fineline Cube May 16, 2025

China’s Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has obtained market authorization from China’s...

Company Drug

North China Pharma Wins NMPA Approval for Clinical Trials of Recombinant Tetanus Vaccine

Fineline Cube May 16, 2025

China-based North China Pharmaceutical Group Corporation (SHA: 600812) announced that it has received clinical trial...

Company Deals

Rznomics and Eli Lilly Collaborate on RNA-Editing Therapies for Sensorineural Hearing Loss

Fineline Cube May 16, 2025

South Korea-based RNA-based therapeutics specialist Rznomics Inc. has entered into a strategic global research collaboration...

Company

Merck KGaA Reports Q1 2025 Financials with 2.5% Organic Sales Growth

Fineline Cube May 16, 2025

Merck KGaA (ETR: MRK) released its Q1 2025 financial results, reporting a 2.5% year-on-year (YOY)...

Company Drug

CanSino Biologics Gets Indonesian Approval for Phase I Trial of Inhalable Tuberculosis Vaccine

Fineline Cube May 16, 2025

China-based CanSino Biologics Inc. (HKG: 6185), a specialist in vaccine development, has announced that it...

Company Drug

Haisco Pharma’s HSK21542 Approved by NMPA for Post-Abdominal Surgery Pain

Fineline Cube May 16, 2025

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received marketing approval...

Company Medical Device

Lifetech Scientific’s Aortic Arch Stent System Approved by China’s NMPA

Fineline Cube May 16, 2025

China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received marketing approval from...

Company Drug

Sihuan Pharmaceutical’s Bireociclib Approved by NMPA for Advanced Breast Cancer

Fineline Cube May 16, 2025

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...

Company Drug

CANbridge’s Velaglucerase β Approved by NMPA for Gaucher’s Disease Long-Term Therapy

Fineline Cube May 16, 2025

China-based CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that the National Medical Products Administration (NMPA) has...

Company Deals

Merck KGaA and JD Health Launch Online Thyroid Care Center in China

Fineline Cube May 16, 2025

The Thyroid Care Center on the JD Health platform, a joint initiative between German pharmaceutical...

Company Drug

Novartis’ Scemblix Approved by NMPA for Newly Diagnosed Ph+ CML-CP Patients

Fineline Cube May 15, 2025

Swiss pharmaceutical company Novartis (NYSE: NVS) announced that it has received marketing approval from China’s...

Company Drug

AbbVie’s Emrelis Granted FDA Accelerated Approval for NSCLC with High c-MET Overexpression

Fineline Cube May 15, 2025

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to AbbVie’s (NYSE: ABBV)...

Company

BeiGene Announces Plans to Relocate Headquarters to Switzerland from Cayman Islands

Fineline Cube May 15, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), the China-based oncology company that has proposed...

Company Drug

Chengdu Kanghong’s KH607 Approved for Clinical Trials in Postpartum Depression

Fineline Cube May 15, 2025

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) has announced that it has received...

Medical Device Policy / Regulatory

NMPA Releases Updated List of Medical Devices Exempted from Clinical Evaluation

Fineline Cube May 15, 2025

The National Medical Products Administration (NMPA) has released the latest version of the “List of...

Company Drug

Boehringer Ingelheim’s Nerandomilast Filing Accepted for Review in Progressive Pulmonary Fibrosis

Fineline Cube May 15, 2025

Boehringer Ingelheim announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products...

Company Drug

Novartis’ Kisqali Receives NMPA Approval for High-Risk Early Breast Cancer

Fineline Cube May 15, 2025

Switzerland-based Novartis (NYSE: NVS) announced this week that it has received another indication approval from...

Company Deals

MGI Tech Partners with Genoks to Enhance Clinical Testing Services in Türkiye

Fineline Cube May 15, 2025

China-based gene sequencing specialist MGI Tech Co., Ltd. (SHA: 688114) has entered into a strategic...

Posts pagination

1 … 162 163 164 … 667

Recent updates

  • BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color
  • Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy
  • AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting
  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.